Leap Therapeutics Newsroom

LEAP Awarded "Overall Practice Management Solution of the Year" Again by LegalTech Breakthrough

PR NewswireNov 26 15:27 ET

Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference

PR NewswireNov 26 07:00 ET

Buy Recommendation for Leap Therapeutics: Promising Phase 2 Trial Developments and Stable Financial Outlook

TipRanksNov 15 06:28 ET

Leap Therapeutics | 8-K: Leap Therapeutics Reports Third Quarter 2024 Financial Results

SECNov 13 07:13 ET

Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate

BenzingaNov 13 07:12 ET

Leap Therapeutics: Cash Position Expected to Fund Operations Into 2Q 2026 >LPTX

Dow JonesNov 13 07:06 ET

Express News | Leap Therapeutics Q3 Operating Income USD -17.855 Million

ReutersNov 13 07:00 ET

Press Release: Leap Therapeutics Reports Third Quarter 2024 Financial Results

Dow JonesNov 13 07:00 ET

Leap Therapeutics 3Q Loss $18.2M >LPTX

Dow JonesNov 13 07:00 ET

Leap Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 06:52 ET · Announcements

Leap and Siro Unite to Unlock Total Sales Transparency With New Integration in SalesPro

PR NewswireOct 28 08:00 ET

Leap Therapeutics Completes Enrollment in Part B of DeFianCe Study

TipRanksSep 30 07:11 ET

Express News | Leap Therapeutics Announces Completion of Enrollment in Part B of the Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

ReutersSep 30 07:00 ET

Leap LLC Secures Spot on the Inc. 5000 Fastest-Growing Companies List for the Fourth Consecutive Year

PR NewswireAug 14 08:03 ET

Baird Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $9

Moomoo NewsAug 13 10:31 ET · Ratings

Optimistic Buy Rating on Leap Therapeutics Amid Promising Phase 2 Cancer Trial Outcomes

TipRanksAug 13 09:52 ET · Ratings

H.C. Wainwright Maintains Leap Therapeutics(LPTX.US) With Buy Rating, Maintains Target Price $5.5

Moomoo NewsAug 13 06:31 ET · Ratings

Leap LLC Welcomes Jason Tillery as New Board Member: A Strategic Move to Enhance AI Capabilities

PR NewswireAug 12 08:00 ET

Express News | Leap Therapeutics Q2 2024 GAAP EPS $(0.52) Misses $(0.43) Estimate, Cash And Cash Equivalents Totaled $78.5M At June 30, 2024, Expected To Fund Leap's Operating And Capital Expenditures Into Q2 Of 2026

BenzingaAug 12 07:25 ET

Leap Therapeutics GAAP EPS of -$0.52 Misses by $0.09

Seeking AlphaAug 12 07:22 ET